Navigation Links
Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc.
Date:1/15/2014

an event, change or other circumstances that gives rise to the termination of the merger agreement;
  • a governmental or regulatory approval required for the proposed acquisition of ViroPharma may not obtained, or may be obtained subject to conditions that are not anticipated, or another condition to the closing of the proposed acquisition may not be satisfied;
  • ViroPharma may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners pending the consummation of the proposed acquisition by Shire, or ViroPharma's business may be disrupted by the proposed acquisition, including increased costs and diversion of management time and resources; and
  • difficulties in integrating ViroPharma into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all;

  • and other risks and uncertainties detailed from time to time in Shire's or ViroPharma's filings with the U.S. Securities and Exchange Commission, including their respective most recent Annual Reports on Form 10-K.


    For further information please contact:


        
        Investor Relations
        Eric Rojas, erojas@shire.com, +1-781-482-0999
        Sarah Elton-Farr, seltonfarr@shire.com, +44-1256-894157


        Media
        Jessica Mann, jmann@shire.com, +44-1256-894-280
        Gwen Fisher, gfisher@shire.com, +1-484-595-9836


    '/>"/>
    SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire
    2. Shire Extends Tender Offer for ViroPharma
    3. Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease
    4. MinuteClinic Opens First Clinic Locations in New Hampshire
    5. Block & Leviton LLP Investigates ViroPharma Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Shire PLC.
    6. Shire to Present at the Bank of America Merrill Lynch Global Health Care Conference
    7. Shire to Present at the Morgan Stanley Global Healthcare Conference
    8. Shire Reports 7% Product Sales Growth: Anticipating Double Digit Non GAAP Earnings Growth in 2013
    9. Shire Announces Award Recipients for 2013 US ADHD Scholarship Program
    10. Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
    11. SARcode Bioscience Announces Acquisition by Shire US Holdings Inc.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... Mike Rowe , spokesperson and reality television ... Pharmacy,s 2015 ThoughtSpot conference and tradeshow, which ... Las Vegas, Nev. Best known ... and Discovery Channel,s, "Dirty Jobs," Mr. Rowe spent a decade ... – people whose hard work, sacrifice and value aren,t always ...
    (Date:7/28/2015)...  CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today its results for the ... Pat Mackin, Chairman, President and Chief Executive ... on our growth strategy with solid progress on several ... plans to transition to a direct sales model in ...
    (Date:7/28/2015)... YORK , July 28, 2015 ... late-stage pharmaceutical company focused on the development and ... that new Locilex® microbiology data will be presented ... of Antimicrobial Agents and Chemotherapy and International Society ... (ICAAC/ICC 2015) scientific meeting in San ...
    Breaking Medicine Technology:Mike Rowe to Address Community Pharmacists at ThoughtSpot 2015 2CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14Dipexium Pharmaceuticals' Pexiganan Demonstrates Microbiological Activity Against Pathogens Resistant to other Topical Antibiotics 2Dipexium Pharmaceuticals' Pexiganan Demonstrates Microbiological Activity Against Pathogens Resistant to other Topical Antibiotics 3
    ... A study comparing,the formulations of isosorbide dinitrate (ISDN) ... II, and BiDil, the proprietary,fixed dose combination, used ... no bioequivalence. Non-bioequivalence,in the formulations used may explain ... results in decreasing mortality. Using,identical amounts of active ...
    ... 26, 2007 /PRNewswire/ -- DiObex,Inc., a privately- ... therapeutics to treat metabolic diseases, today,announced positive ... novel Cortisol,Synthesis Inhibitor. , In a recently ... 2 diabetes were,treated for two weeks to ...
    Cached Medicine Technology:Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 2Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 3Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 4Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 5Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 2Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 3
    (Date:7/28/2015)... ... 28, 2015 , ... The Denver Foundation and Blair-Caldwell African ... Exhibited,” a photographic and narrative exploration of African American giving, which runs August ... , Denver is one of only ten cities to host “The Soul of ...
    (Date:7/28/2015)... ... July 28, 2015 , ... Representatives with CareMed Urgent ... full support of National Immunization Awareness Month, which is the month of August. ... serious illnesses like the flu, measles, and pneumonia, adults need to get their ...
    (Date:7/28/2015)... FAIRFAX, Virginia (PRWEB) , ... July 28, 2015 , ... ... in the Washington, D.C. technology community for over 20 years, has selected Lisa Dezzutti, ... for the upcoming year. , “I am excited to serve this organization that empowers ...
    (Date:7/28/2015)... , ... July 28, 2015 , ... Egg freezing ... the procedure to help ensure future fertility. As Dr. Michael Kettel explained ... freezing is an option that wasn’t available for previous generations who had to make ...
    (Date:7/28/2015)... ... ... to WFTV on July 15th heroin overdose rates have increased by 270 ... statistic Orlando suffers at least one death weekly as a direct result of a ... officials are struggling to keep apace with its distribution. Officers rely on inside information ...
    Breaking Medicine News(10 mins):Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2Health News:CareMed Urgent & Primary Care Supports National Immunization Awareness Month 2Health News:CareMed Urgent & Primary Care Supports National Immunization Awareness Month 3Health News:Lisa Dezzutti Named President of Women in Technology (WIT) Board of Directors 2Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 2Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3
    ... , , Covers Europe, Middle East and ... , Includes Licensing Option and Development Funding for NGX-1998 ... June 22 NeurogesX, Inc. (Nasdaq: NGSX ) and Astellas ... Inc. announced today that the companies have entered into an exclusive Distribution, ...
    ... 22 Bringing the next level of technology ... eClinical solutions provider and subsidiary of PAREXEL International ... that it has launched its industry-leading eClinical Suite ... data across multiple technologies throughout the trial process. ...
    ... ... released by Esco. The videos can be viewed at: http://us.escoglobal.com/resources/hospital-pharmacy-products/videos.php . , ... Hatboro, PA (PRWEB) June ... and education videos for the compounding pharmacy industry. Titled "Pharmacy Isolator Safe ...
    ... To ... and Helen Sher, Founder of The Sher System, a drug-free therapy that has revolutionised the ... , ... -- Rosacea is a common skin condition that causes redness and swelling on the face. ...
    ... People with schizophrenia die from cancer four times as often ... of a new study published in the August 1, 2009 ... American Cancer Society. The study,s results suggest that extra efforts ... in patients with schizophrenia. Schizophrenia is associated with an ...
    ... recipients to suppress their immune systems, has a paradoxical effect ... Vaccine Center have discovered. In experiments conducted in both ... CD8 T cells, which enable the immune system to respond ... encounter. The results were published online ahead of print ...
    Cached Medicine News:Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 2Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 3Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 4Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 5Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 6Health News:Perceptive Informatics Launches the Next Level of Integration in its Industry-Leading eClinical Suite 2Health News:Perceptive Informatics Launches the Next Level of Integration in its Industry-Leading eClinical Suite 3Health News:Perceptive Informatics Launches the Next Level of Integration in its Industry-Leading eClinical Suite 4Health News:Perceptive Informatics Launches the Next Level of Integration in its Industry-Leading eClinical Suite 5Health News:New Compounding Pharmacy Videos Provide Product Information, Teach Safety 2Health News:New Compounding Pharmacy Videos Provide Product Information, Teach Safety 3Health News:Helen Sher Launches Her Rosacea Awareness Campaign 2009 to Help Sufferers of this Distressing Condition 2Health News:Study finds cancer is the second most frequent cause of death in individuals with schizophrenia 2Health News:Transplant drug stimulates immune memory 2
    ... , The new Finnpipette Novus is so user-friendly that ... few minutes. With the intuitive instantly familiar menu and ... functions you need quickly and easily. The large, clear ... names of all functions. The easily accessible two ...
    ... Transfer an Entire Column of a 384 ... and throughput with 384 well plates, you need ... well spacing. Thats exactly what you get with ... Impact2 software (see Impact/Impact2), this innovation was specifically ...
    ... The Seal-Away CS and Alliance ... designed for the introduction of ... coronary sinus from a superior ... Jude Medical's outstanding peel-away introducer ...
    This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
    Medicine Products: